Severe novel influenza A (H1N1) infection in cancer patients by Hajjar, L. A. et al.
Annals of Oncology 21: 2333–2341, 2010
doi:10.1093/annonc/mdq254
Published online 28 May 2010 original article
Severe novel inﬂuenza A (H1N1) infection in cancer
patients
L. A. Hajjar
1, T. Mauad
2, F. R. B. G. Galas
1, A. Kumar
3, L. F. F. da Silva
2, M. Dolhnikoff
2, T. Trielli
1,
J. P. Almeida
1, M. R. L. Borsato
2, E. Abdalla
4, L. Pierrot
4, R. Kalil Filho
1, J. O. C. Auler Jr
1,
P. H. N. Saldiva
2 & P. M. Hoff
5*
Departments of
1Anesthesia and Intensive Care;
2Pathology, Universidade de Sa ˜o Paulo, Sao Paulo, Brazil;
3Section of Critical Care Medicine, University of Manitoba,
Manitoba, Canada; Departments of
4Infectious Diseases;
5Oncology, Universidade de Sa ˜o Paulo, Sa ˜o Paulo, Brazil
Received 8 April 2010; accepted 13 April 2010
Background: The natural history and consequences of severe H1N1 inﬂuenza infection among cancer patients are
not yet fully characterized. We describe eight cases of H1N1 infection in cancer patients admitted to the intensive care
unit of a referral cancer center.
Patients and methods: Clinical data from all patients admitted with acute respiratory failure due to novel viral H1N1
infection were reviewed. Lung tissue was submitted for viral and bacteriological analyses by real-time RT-PCR, and
autopsy was conducted on all patients who died.
Results: Eight patients were admitted, with ages ranging from 55 to 65 years old. There were ﬁve patients with solid
organ tumors (62.5%) and three with hematological malignancies (37.5%). Five patients required mechanical
ventilation and all died. Four patients had bacterial bronchopneumonia. All deaths occurred due to multiple organ
failure. A milder form of lung disease was present in the three cases who survived. Lung tissue analysis was performed
in all patients and showed diffuse alveolar damage in most patients. Other lung ﬁndings were necrotizing bronchiolitis
or extensive hemorrhage.
Conclusions: H1N1 viral infection in patients with cancer can cause severe illness, resulting in acute respiratory
distress syndrome and death. More data are needed to identify predictors of unfavorable evolution in these patients.
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introduction
Patients with malignancies are more susceptible for acquisition
of infections than the general population and are thought to
potentially develop more complications [1]. Due to many
disruptions in both innate and acquired immunity, even
organisms with low virulence potential are able to cause
signiﬁcant morbidity and mortality in cancer patients [2].
During April 2009, a novel swine-origin inﬂuenza A (H1N1)
virus (S-OIV) was identiﬁed in California and in Mexico as the
cause of human respiratory disease, originating a pandemic
[3, 4]. As of February 2010, 700 000 laboratory-conﬁrmed cases
of novel H1N1 inﬂuenza virus and 14 000 deaths have been
reported globally. Most affected patients present with
inﬂuenza-like symptoms and have a benign course [5].
However, patients with comorbidities as cancer and chronic
diseases may show a serious clinical presentation, characterized
by respiratory failure with variable severity [6, 7].
Although the presence of a malignancy is considered to have
a negative impact on the H1N1 disease severity, there are few
reports on clinical outcomes in cancer patients affected by the
disease. Redelman-Sidi et al. [8] recently described a cohort of
45 patients with solid and hematological malignancies with
H1N1 infection. From this population, one single patient
required intensive care admission and there were no viral
infection-related deaths. On the other hand, fatalities have been
described in oncologic patients, particularly in the ones with
hematological malignancies [9].
So far, there are no reports describing clinical characteristics
of cancer patients with a severe form of the disease. These
patients represent a vulnerable population, which require rapid
diagnostic work-up and intensive management in specialized
units. Therefore, we believe that it would be important to
report on the clinical characteristics of cancer patients with
a severe form of the H1N1 infection.
During the 2009 Southern Hemisphere H1N1 pandemics,
Sao Paulo was among the cities with the highest incidence of
disease in Brazil. In this study, we describe the clinical and
pathological ﬁndings in critically ill patients with cancer and
respiratory failure related to novel H1N1 infection admitted to
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patients and methods
This analysis and report was approved by the Institutional Medical Ethical
Committee.
patients
The Instituto do Cancer do Estado de Sa ˜o Paulo is an oncology reference
hospital linked to the Universidade de Sao Paulo Medical School in Brazil.
From June 2009 through November 2009, eight patients with cancer were
admitted in its ICU due to severe H1N1 infection.
Clinical features were prospectively collected through a database that
included demographic data, preexisting medical conditions, status of
cancer, previous cancer treatment, functional scores, risk scores and organ
dysfunction. At admission, family members were asked about patients’
status performance using the Karnofsky performance status scale.
Clinical and laboratorial data at admission and during ICU stay are
described, including the management of respiratory support and
nonventilatory strategies. Data for the Simpliﬁed Acute Physiology Score II
(SAPS II) and for the Acute Physiology And Chronic Health Evaluation
(APACHE II) were reported as the worst value within 24 h after ICU
admission. A daily evaluation of organ function according to the Sequential
Organ Failure Assessment (SOFA) score was performed
Radiological ﬁndings were evaluated through X-ray in all patients and
computerized tomography when appropriate.
The in vivo diagnosis of H1N1 infection was conﬁrmed by real-time RT-
PCR (rRT-PCR) test using nasopharyngeal swab specimens, in accordance
with guidelines from the Centers for Disease Control and Prevention
(CDC) [10].
autopsies
Five patients who died had their autopsies performed in the Department of
Pathology of the Universidade de Sao Paulo. The pathological ﬁndings on
part of this population have been previously described by our group [11].
Tissue fragments were formalin ﬁxed, parafﬁn embedded and
hematoxylin–eosin stained. For lung sections, Grocott, Brown–Hopps and
Ziehl–Neelsen stainings were performed for the identiﬁcation of fungi,
bacteria and acid-fast bacilli, respectively. Lung fragments were sent for
microbiological investigation using rRT-PCR to the Instituto Adolfo Lutz
in Sao Paulo. Seasonal inﬂuenza A and swine inﬂuenza A detection was
performed using the CDC protocol [10]. The RT-PCR test used for bacteria
identiﬁed DNA from Haemophilus inﬂuenzae and Streptococcus pneumoniae.
results
baseline characteristics
Table 1 shows the baseline characteristics of the eight patients.
Patient ages ranged from 55 to 65 years (median, 58 years).
Four patients (50%) were male. All patients (100%) had
preexisting medical conditions other than the neoplasm. Most
of the patients presented no functional impairment before the
infection—seven patients (87.5%) had Karnofsky scale >70.
Five patients (62.5%) had solid neoplasms and three patients
(37.5%) had hematological malignancies. Two patients had
been submitted to chemotherapy in the last 4 weeks (Table 1).
However, most patients were considered as having active
disease regarding cancer status (seven patients, 87.5%). Four
patients (50%) had metastatic disease. The patient with
myeloﬁbrosis had been submitted to stem-cell transplantation 1
year ago. All patients presented cough and fever, most patients
had myalgia and dyspnea (87.5%). Hemoptysis, rhinorrhea and
wheezing were present in 25% and diarrhea was related by
12.5% of patients.
clinical presentation and outcome
At admission, all patients presented with signs of systemic
inﬂammatory response syndrome, deﬁned as two or more of
the signs and symptoms described in Table 2. All patients had
fever or hypothermia and tachypnea. Leukocytosis was present
in 75% of cases. At admission, only two patients were
hypotensive (25%). However, hypoxemia was present in 100%
of cases, and four patients (50%) had oxygen saturation <90%
at admission (Table 2). Initially, lung disease was in most cases
localized in one or two quadrants of lung (75%). However,
most patients developed a more extensive and progressive
Table 1. Baseline characteristics of patients admitted in the oncologic
ICU with H1N1 infection
Variable n (%)
Male sex—number/total number 4/8
Age (years), median (range) 58 (55–65)
Comorbidities
Cardiovascular chronic disease 3 (38)
Hypothyroidism 2 (25)
Chronic obstructive pulmonary disease 1 (13)
Diabetes 2 (25)
More than one comorbidity 3 (37)
Karnofsky (at least 30 days before ICU admission)
>70 7 (88)
<70 1 (13)
Oncology diagnosis
Hematological disease 3 (38)
Myeloﬁbrosis 1 (13)
Chronic lymphocitic leukemia 1 (13)
Multiple myeloma 1 (13)
Solid neoplasm 5 (63)
Breast cancer 1 (13)
Prostate cancer 1 (13)
Esophagus cancer 2 (25)
Rectal melanoma 1 (13)
Metastatic disease (yes/no) 4/8
Chemotherapy no. (at least 4 weeks before hospitalization)
Yes 2 (25)
No 6 (75)
Active disease (yes/no) 7/1
Stem-cell transplantation no. 1 (13)
Presenting manifestations
Cough 8 (100)
Fever 8 (100)
Myalgia 7 (88)
Dyspnea 7 (88)
Hemoptysis 2 (25)
Rhinorrhea 2 (25)
Wheezing 2 (25)
Diarrhea 1 (13)
ICU, intensive care unit.
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quadrants. In all the eight patients, the diagnosis of acute
respiratory distress syndrome (ARDS) could be established
based on the presence of bilateral pulmonary inﬁltrates, a ratio
of the partial pressure of arterial oxygen to the fraction of
inspired oxygen (PO2/FiO2) £200 and no clinical evidence for
an elevated left atrial pressure.
Due to rapidly progressive hypoxemia (PO2/FiO2 117) and
the rapid worsening of lung inﬁltrates (Figure 1), ﬁve patients
(62.5%) needed invasive mechanical ventilation. Four patients
were intubated in the ﬁrst 24 h of ICU and one patient 48 h
after unsuccessful noninvasive ventilation (NIV). NIV was
successfully used in three patients (37.5%), who had milder
forms of disease as showed by a computerized tomography that
revealed sparse bilateral inﬁltrate (Figure 2).
Patients who needed mechanical ventilation were managed
with pressure-cycled ventilation, with a low tidal volume (target
6 ml/kg) open-lung strategy of ventilation, and a positive end-
expiratory pressure (PEEP) titrated based on FiO2 for goal
plateau pressure (Pplat) < 30 cm H2O and SpO2 88%–90%
according to ARDS Network protocol. In some cases, due to
refractory hypoxemia, PEEP levels of 14 to 16 cm H2O were
applied. In all patients, recruitment maneuvers were used—
continuous positive airway pressure 35–40 cm H2O for 30 s—
with short-term improvements in oxygenation in three of ﬁve
patients (initial mean oxygen saturation rate increased from
88% to 94%). Neuromuscular blockade was used in two
patients (Table 2). Despite the aforementioned ventilatory
strategy, this particular group of patients developed
refractory persistent hypoxemia. Lung mechanics of patients
showed very low static and dynamic compliance and high
airway resistance.
Most patients presented risk scores that predicted high-risk
mortality (APACHE II 24 and SAPS II 52). Respiratory failure
was the most commonly encountered dysfunction, followed by
cardiovascular, renal and hematological failures. Two patients
needed dialysis. Most patients needed vasopressor and
inotropic drugs. Patients presented with a serious, rapidly
Table 2. Clinical ﬁndings at hospital admission and respiratory variables
of patients with conﬁrmed S-OIV infection
Clinical ﬁndings and symptoms n (%)
Total of patients 8
SIRS 8 (100)
Fever or hypothermia (T >38 or <36 C) 8 (100)
Tachypnea (RR >20 breaths/min) 8 (100)
Tachycardia (HR >100 beats/min) 5 (63)
Leukocytosis (>10 000 mm
3) 6 (75)
Leukopenia (<4000/mm
3) 2 (25)
Hypotension (systolic blood pressure < 90 mmHg)
on admission
2 (25)
Hypoxemia on admission 8 (100)
SpO2 < 90% 4 (50)
90% < SpO2 < 95% 4 (50)
SpO2 > 95% 0 (0)
Number of quadrants with opacities in initial
radiography
None 2 (25)
One quadrant 3 (38)
Two quadrants 3 (38)
Three or four quadrants 0 (0)
Number of quadrants with opacities in radiography after 24 h admission
None 0 (0)
One quadrant 1 (13)
Two quadrants 2 (25)
Three or four quadrants 5 (63)
Invasive mechanical ventilation/noninvasive
ventilation
5 (63)
Timing of orotracheal intubation (h) related to ICU admission
Before ICU admission 1 (13)
0–24 3 (38)
24–48 0 (0)
>48 1 (13)
Respiratory and ventilatory variables in ﬁve
mechanically ventilated patients
5 (100)
PaO2/FiO2 < 200, median (range) 118 (64–170)
PEEP, median (range) 13 (10–20)
Pressure-cycled ventilation 5 (100)
Open-lung approach 5 (100)
Neuromuscular blockade 2 (40)
Recruitment maneuvers 5 (100)
Refractory hypoxemia 5 (100)
Apache II score (median) 24
SAPS II (median) 52
Admission SOFA (median) 10
Organ dysfunction at admission
Respiratory failure 8 (100)
Liver failure 0 (0)
Central nervous system failure 4 (50)
Renal failure 6 (75)
Hematological failure 5 (63)
Cardiovascular failure 6 (75)
Use of vasopressor and inotropic
Norepinephrine 6 (75)
Vasopressin 3 (37)
Dobutamine 4 (50)
SOFA on day 2 (median) 16
Use of antibiotics 8 (100)
Table 2. (Continued)
Clinical ﬁndings and symptoms n (%)
Onset of oseltamivir therapy after hospital admission (h)
0–6 2 (25)
6–12 4 (50)
12–24 2 (25)
>24 1 (13)
Use of corticosteroids 8 (100)
Time from hospital admission to ICU arrival (h),
median (range)
21 (7–60)
Death 5 (63)
Days from ICU to death, median (range) 3 (1–8)
S-OIV, swine-origin inﬂuenza A virus; SIRS, systemic inﬂammatory
response syndrome; RR, respiratory rate; HR, heart rate; SpO2,
oxygen peripheral saturation; ICU, intensive care unit; PaO2, oxygen
arterial pressure; FiO2, oxygen inspired fraction; SAPS II, Simpliﬁed Acute
Physiology Score II; SOFA, Sequential Organ Failure Assessment; T,
temperature; PEEP, positive end-expiratory pressure.
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score after 24 h of ICU.
Oseltamivir was initiated early in all patients. Corticosteroids
were administered in all patients admitted in the ICU, at a dose
of methylprednisolone 2 mg/kg/day. Antibiotics were
empirically administered in all patients due to clinical suspicion
of bacterial coinfection. Despite early treatment, these patients
had a high mortality rate, with ﬁve deaths (62.5%). The median
period from admission to death was 3 days (1–8). Interestingly,
three patients who died showed persistent positive rRT-PCR in
nasopharyngeal swabs after 5 days of oseltamivir.
laboratory ﬁndings
H1N1 infection was conﬁrmed in all eight patients by rRT-PCR
testing of nasopharyngeal swabs.
Hematological evaluation showed leukocytosis (median
16 100/mm
3) and anemia (median hemoglobin 9.3 g/dl) in
majority of cases. Also, signs of tissue hypoxia as acidosis
(median pH 7.2), high levels of lactate (median 4.2 mmol/l)
and low levels of base excess (median 4.5 mEq/l) were noted in
patients since admission until death. Reactive protein-C ranged
from 99 to 447, revealing inﬂammatory response associated or
not with coinfection (Table 3).
During evolution, bacterial coinfection was diagnosed in
seven patients: Staphylococcus aureus in blood stream in one
patient, urinary tract infection due to Enterococcus faecalis in
one patient and pneumonia due to Pseudomonas aeruginosa
i no n ec a s ea n dd u et oS. pneumoniae in four other cases.
Also, one patient presented urinary tract infection due to
Candida.
Figure 1. Radiographic ﬁndings in patients admitted in intensive care unit with swine-origin inﬂuenza A virus infection. The ﬁrst panel shows
a radiological sequence of three X-rays at admission (A), 12 h (B) and 24 h (C) after admission of a patient who developed progressively respiratory failure
needing mechanical ventilation. The second panel shows X-rays at admission (D), 4 h (E) and 12 h (F) after admission of a patient who developed
respiratory failure, needing mechanical ventilation.
Figure 2. Chest computerized tomography of a patient who showed a milder form of lung disease (A), improving in intensive care unit after noninvasive
ventilation (B).
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An autopsy was performed in the ﬁve patients who died, and
a summary of the ﬁndings is presented in Table 4.
All patients presented extensive pathological alterations in
the lungs; lungs were heavy, diffusely edematous and with
variable degrees of hemorrhage. Diffuse alveolar damage
(DAD) was present in most of the patients, but as previously
described, there were three distinct patterns of pulmonary
pathological changes [11, 12]: (i) four patients had classic
exudative DAD, with alveolar and interstitial edema, hyaline
membranes and reactive pneumocytes; (ii) one patient
(esophagus neoplasm) had DAD and severe necrotizing
bronchiolitis (NB) characterized by extensive necrosis of the
bronchiolar wall and dense neutrophilic inﬁltrate within the
bronchiolar lumen and (iii) one patient (myeloﬁbrosis)
presented with exudative DAD with an intense hemorrhagic
component (Figure 3). Only one of the ﬁve patients did not
present acute interstitial changes. In this patient with
esophageal cancer, death was secondary to pulmonary
thromboembolism and bacterial pneumonia. Two patients had
pulmonary thromboembolism (two patients with esophagus
neoplasm). In four of ﬁve patients, bronchopneumonia
coinfection due to S. pneumoniae was conﬁrmed at autopsy
(Figure 3).
Metastatic disease was present in all patients with solid
neoplasms, and two of those had lung involvement by tumor.
All patients had atrophic or nonreactive white pulp in the
spleen (Figure 3). In the lymph nodes, nonreactive follicles and
sinusoidal erythrophagocytosis were found. The liver showed
erythrophagocytosis and a few mononuclear inﬂammatory cells
in the sinusoids in all patients and variable degrees of shock-
related centrilobular necrosis. The bone marrow was
hypocellular in four of ﬁve patients. All patients had mild/
moderate kidney acute tubular necrosis. No patient had
histological signs of encephalitis, myocarditis or myositis.
discussion
We report the clinical and pathological ﬁndings from eight
patients with cancer and severe H1N1 infection who were
admitted to an oncologic ICU during the winter period of the
2009 pandemic in Sao Paulo, Brazil. These patients were
characterized by having active malignant disease, comorbidities
and difﬁcult to manage rapidly progressive acute respiratory
failure.
Viral infections may represent up to 26% of the infections
identiﬁed in cancer patients with pulmonary inﬁltrates. In
a large study examining viral infections in hematological cancer
patients, pneumonia was observed in 31% of the cases, and the
overall mortality was 15% [12]. In this study, inﬂuenza A was
the most common isolated agent, and the only independent
predictor of fatal outcome was an absolute lymphocyte count
£200 cells/ml.
Clinical outcomes in cancer patients with H1N1 infection
have not been fully characterized yet. Due to potential severity
of H1N1 infection in this group of patients, Crawford et al. [13]
recommended during the 2009 pandemic that patients with
cancer who are receiving chemotherapy and develop fever
should be admitted to a hospital and receive oseltamivir after
swab collection. In addition, patients with febrile neutropenia
should be treated according to the usual protocol with the
addition of oseltamivir.
Kharfan-Dabaja et al. [14] ﬁrst reported H1N1 infection in
two allogeneic hematopoietic cell transplantation recipients. In
one case, the patient presented with fever, myalgia, sore throat
and diarrhea without evidence of hypoxemia or lung
progressive inﬁltrates. After treatment with oseltamivir,
ciproﬂoxacin and doxycicline, the symptoms resolved without
sequelae. In the second case, pulmonary symptomatology
continued to deteriorate despite aggressive polymicrobial
treatment, requiring mechanical ventilation and ultimately the
patient died from respiratory failure [14]. Redelman-Sidi et al.
[8] recently described 45 patients with cancer and/or
hematological conditions and H1N1 infection at the Memorial
Sloan-Kettering Cancer Center, with no reports of mortality or
serious morbidities. In this report, only one patient was
admitted in the ICU and did not need mechanical ventilation.
In these patients with cancer, mortality was very high. The
differences in outcomes may be related to speciﬁc
characteristics of our population, including high prevalence of
metastatic disease, comorbidities and high incidence of
bacterial coinfection. Differently from the MSKCC experience
[8], most patients in our series initially presented with signs
and symptoms of lung disease—hypoxemia, dyspnea and
tachypnea—instead of only inﬂuenza symptoms.
The serious clinical presentation of the novel Inﬂuenza A
(H1N1) infection in some cancer patients should be expected.
Patients with cancer now live longer and immunosupression
from malignant disease or its treatment renders many
susceptible to infections [15]. Indeed, most of the patients in
this series developed bacterial coinfections. The altered
immunological response of these patients may contribute to the
Table 3. Laboratorial data at admission and during intensive care unit
stay in patients with S-OIV infection
Variable Value (no.)
Leukocyte · 10
3 per mm
3, median (range) 16.1 (1.26–84)
Hemoglobin (g/dl), median (range) 9.3 (6.8–14)
Platelets · 10
3 per mm
3 median (range) 166 (25–411)
pH, median (range) 7.22 (7.19–7.40)
BE, median (range) 24.5 (210.6 to 2.6)
Lactate (mmol/l), median (range) 4.2 (2.2–6.4)
Serum creatinine, median (range) 3.0 (0.34–11.23)
BUN (mg/dl), median (range) 46 (12–82)
Reactive protein-C, median (range) 224 (99–447)
Positive cultures for other pathogens
Blood 1
Staphylococcus aureus 1
Urine 2
Enterococcus faecalis 1
Candida albicans 1
Respiratory secretion 1
Pseudomonas aeruginosa 1
Streptococcus pneumoniae 4
S-OIV, swine-origin inﬂuenza A virus; BE, base excess; BUN, blood urea
nitrogen.
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Patient/age Gender Neoplasm Metastasis Lung pathology Bronchopneumonia Bacterial culture Lung PCR
for bacteria
Extrapulmonary ﬁndings
01/58 years F Myeloﬁbrosis Absent DAD and alveolar
hemorrhage
Present Streptococcus
pneumoniae
Positive Acute tubular necrosis,
bone marrow ﬁbrosis,
liver hemosiderosis,
white pulp depletion in
spleen
02/56 years F Rectal melanoma Pleura, lung, liver, heart,
lymph nodes, adrenal
glands
Exudative DAD Present S. pneumoniae Positive Acute tubular necrosis,
liver necrosis, white
pulp depletion in
spleen
03/56 years F Breast carcinoma Brain, lung, lymph nodes,
diaphragm
Exudative DAD Absent Negative Negative Acute tubular necrosis,
brain necrosis,
hypocellular bone
marrow, white pulp
depletion in spleen
04/60 years M Esophagus cancer Neck lymph nodes No virus-related
pulmonary changes
Present S. pneumoniae and
Pseudomonas
aeruginosa
Negative Acute tubular necrosis,
white pulp depletion in
spleen, hypocellular
bone marrow, lung
thromboembolism
05/55 years M Esophagus cancer Liver, kidney, thoracic
lymph nodes
DAD and necrotizing
bronchiolitis
Present S. pneumoniae Negative Liver necrosis,
hypocellular bone
marrow, white pulp
depletion in spleen
lung thromboembolism
F, female; M, male; DAD, diffuse alveolar damage.
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0development of more severe forms of disease. In our study,
three cases still excreted virus after 5 days in the ICU, as already
reported [16]. Prolonged periods of viral shedding could be
associated to disease severity [17] and perhaps with an
oseltamivir-resistant strain of the virus [18].
Respiratory failure occurred in all patients who required ICU
care and was characterized by rapidly progressive bilateral lung
inﬁltrates with refractory hypoxemia and low left atrial
pressure—ARDS. Most patients needed mechanical ventilation
(ﬁve of eight), and they were all treated with protective
strategies according to the ARDS Network protocol [19]. In all
these patients, recruitment maneuvers were applied, with just
transient improvement in oxygenation (initial median oxygen
saturation rate increased from 88% to 94%), reﬂecting the
extensive lung involvement of disease. In some cases of severe
H1N1 infection, extracorporeal membrane oxygenation [20]
has been proposed as an alternative support therapy with
promising results [21, 22].
Based on previous cases of H1N1 infection in noncancer
patients, Ramsey et al. [6] described a signiﬁcant proportion of
patients with hypoxemic respiratory failure, specially when
associated with comorbidities. Early intubation and admission
in the ICU is prudent, given the rapid progression of
hypoxemia. Based on current evidence, authors recommend
patients should be managed with a low tidal volume open-lung
strategy of ventilation, with PEEP titrated based on FiO2 to
achieve adequate SpO2 and low Pplat [21, 22].
This strategy was performed in all studied patients of our
series; however, despite that there was no adequate response
and all patients who required mechanically ventilated died with
refractory hypoxemia and multiple organ failure. Similar to our
ﬁndings, in a Mexican series of S-OIV cases, of 12 patients who
needed mechanical ventilation, 7 died [23].
Three patients presented with a milder form of lung disease,
responding well to NIV, and with progressive improvement of
hypoxemia. There is some controversy around the clinical
Figure 3. Representative photomicrographs of pulmonary and extrapulmonary changes in cancer patients with fatal H1N1 infection. A to C show different
patterns of pulmonary involvement. (A) Exudative diffuse alveolar damage (DAD) with numerous hyaline membranes (arrows) within alveolar spaces. (B)
Extensive lung hemorrhage associated with DAD. (C) Necrotizing bronchiolitis. The bronchiole (Br) is partially ﬁlled with necrotic epithelial and
inﬂammatory cells. (D) Bronchopneumonia. The alveolar spaces (Alv) are ﬁlled with dense inﬁltration of macrophages and neutrophils. (E) Lung
metastasis (M) from primary breast cancer, P = pulmonary tissue. (F) Spleen with depleted white pulp (arrow) and expanded red pulp. Scale bars: A–E:
100 lm, F:5 0lm.
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NIV may be considered as a mode of ventilation for hypoxemic
respiratory failure, there are concerns about its usefulness in an
infectious epidemic [24]. In the Canadian experience, 30% of
patients were noninvasively ventilated on admission, but 85%
of these patients required subsequent intubation and invasive
ventilation [6]. In addition, NIV machines have no bacterial or
viral ﬁlters and do generate aerosols. There are often leaks from
the mask, and it has to be removed sometimes for nursing care
[24]. During the pandemic, NIV was associated with
transmission of disease to health care workers [25].
In our study, we detected bacterial coinfection in seven of the
eight patients. The CDC reported that 29% of fatal cases in the
United States presented at least one bacterial coinfection [26].
Mauad et al. [11] found evidence of bacterial coinfection in
38% of fatal cases in Sao Paulo.
The presented incidence of 87% of bacterial coinfection
might explain in part the high mortality rate of this group,
despite early antimicrobial therapy. Interestingly, biochemical
and hematological data could not discriminate H1N1
infection from sepsis of bacterial origin in this group of
patients.
Corticosteroids were administered to all patients as Meduri
et al. [27] recommend in ARDS cases with low PO2/FiO2.
Steroid use has been reported in some cases of H1N1-
associated ARDS without any adverse outcome [28].
However, some authors discuss the potential adverse effects of
steroids in H1N1 infection, including higher mortality
possibly related to virus spreading [29]. Although there is no
consensus about its efﬁcacy in this disorder, and despite the
belief that corticosteroid could reduce pulmonary
inﬂammation and ﬁbrosis in severe cases, our poor results
suggest that this strategy will need to be carefully reevaluated
in the future.
By performing autopsies in the fatal cases in this population
we could determine that the cause of death in all patients was
extensive involvement of the lungs and alterations secondary to
multiple organ failure in major organs such as kidney and liver
[11]. Patients had severe DAD associated with severe NB and
alveolar hemorrhage. Further, autopsy results showed that
patients had metastatic disease and signs of cellular
immunosuppression as depletion of white pump view on
spleen analysis. Certainly, autopsies contributed to a better
characterization of these patients.
This report has some limitations. The unicentric
characteristics of the study and the small sample size do not
allow for deﬁnite conclusions about severe H1N1 presentation
in oncologic patients. We characterized H1N1 infection in
a selected population of patients with neoplasm, with a high
incidence of metastatic disease and who needed ICU care. Our
ﬁndings certainly describe the most serious presentation of
disease.
The importance of describing this serious form of disease in
patients with cancer is to reinforce prevention strategies in this
group, as to recommend vaccine, hygienic measures,
prophylactic antiviral treatment in cases of contact and
adequate isolation in cases of hospital admission due to H1N1
infection [30, 31]. Also, a better understanding of clinical and
pathological ﬁndings in the group of cancer patients could
guide ventilator management and nonventilatory strategies to
obtain lower rates of mortality.
In summary, our report of cancer patients highlights the
severity of the Inﬂuenza A (H1N1) pandemic in this vulnerable
population and the urgent need to establish speciﬁc protocols
of care and management strategies designed to face this health
care challenge.
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